Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
SEEGENE

Horizon and AstraZeneca Announce Oncology Agreement

By Labmedica International staff writers
Posted on 21 Jan 2014
Horizon Discovery (Horizon; Cambridge, United Kingdom) and AstraZeneca (London, United Kingdom) have entered into research collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.

Under the terms of the agreement, Horizon will receive an undisclosed upfront payment, and is eligible for subsequent payments of up to USD 88 million in milestones if compounds are developed by AstraZeneca against an undisclosed number of targets identified through the research collaboration.

A defined set of genotypes will be queried by Horizon for synthetic lethality. Horizon will carry out in vitro screening activities using its proprietary small interfering RNA (siRNA) platform. RNAi hits resulting from this first stage will then be validated by Horizon, through techniques including pathway analysis, confirmation of activity in endogenously mutant vs. wild type cell lines (X-MAN), functional assays, or gene knock-in/knockout assays. AstraZeneca may exercise exclusivity over any validated targets.

Synthetic lethality occurs where the combination of mutations in two or more genes leads to cell death, but a mutation in just one of those genes does not. Synthetic lethal screens have demonstrated great potential in oncology, as these pairs of mutations can be used to selectively kill cancer cells, but leave normal cells relatively unharmed.

Horizon’s X-MAN isogenic cell lines accurately model the disease-causing mutations found in patients with cancer, and increasingly in other diseases. Horizon creates the isogenic cell lines using its precision genome-editing GENESIS platform, comprising rAAV, ZFN and CRISPR technologies, to engineer specific disease-related mutations into model cell lines.

These models help scientists understand how complex genetic diseases manifest themselves in patients. They can reduce the cost of bringing to market new personalized therapies by reorganizing many aspects of drug development such as target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.

Dr Darrin M Disley, CEO at Horizon Discovery, said: “We are delighted to have extended our relationship with AstraZeneca’s oncology team with this latest agreement. Horizon is uniquely placed in the translational genomics field for investigation of synthetic lethality, as our X-MAN isogenic disease models incorporate patient-relevant genetic context, and allow large scale, timely, and systematic screens for the first time. Combined with our high-throughput RNAi and bioinformatics technology platforms, we have a powerful offering.”

Susan Galbraith, head of the Oncology Innovative Medicines Unit at AstraZeneca, commented: “AstraZeneca’s strategy of collaborating with innovative organizations like Horizon allows us to broaden our oncology research efforts and complement our own internal capabilities.

Partnering Horizon’s excellent capabilities in synthetic lethal screens and validation with our strong oncology discovery and development expertise offers real potential to address the need for novel cancer therapeutics, and ultimately to make a difference to patients.”

Related Links:

Horizon Discovery
AstraZeneca



ADVANCED INSTRUMENTS
GREINER-BIO-ONE
PURITAN MEDICAL
BioConferenceLive

Channels

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.